A measured look at EADV 2026 telikibart and rezpegaldesleukin results, including response rates, study limitations and questions for dermatology care.
On October 15, 2026, HCPLive reported late-breaking EADV 2026 findings for telikibart in atopic dermatitis and rezpegaldesleukin in alopecia areata. The update covered phase 3 eczema results and 52-week phase 2b hair-loss findings. Together they offer a focused research update for readers following emerging skin and hair treatments.
The central findings concern different questions: how telikibart performed against placebo and how a rezpegaldesleukin response measure changed during longer follow-up. Understanding that distinction is more useful than treating the results as a single story about treatment success.
According to HCPLive, telikibart met both coprimary endpoints in its phase 3 atopic dermatitis trial. Those endpoints were EASI-75 and IGA 0/1. The reported placebo comparison gives the eczema findings a defined reference point at week 16.
For alopecia areata, HCPLive identified the findings as coming from the phase 2b REZOLVE-AA study. It described rezpegaldesleukin as a Treg-inducing IL-2 receptor agonist. The central observation was a later increase in the proportion of participants meeting the reported hair-loss response threshold.
These are two separate research developments rather than competing treatments for the same condition. One concerns atopic dermatitis response during a placebo-controlled period. The other brings attention to the timing of response in alopecia areata.
For background on the hair-loss condition itself, Younell’s guide to understanding alopecia areata provides context alongside this trial update.
The clearest way to interpret the numbers is to keep each endpoint attached to its treatment group and assessment time. A percentage separated from those details loses much of its meaning.
HCPLive reported the following results from the phase 3 atopic dermatitis trial:
Both reported response rates were higher with telikibart than with placebo. They are separate endpoint results from the same assessment time, not interchangeable descriptions of a single outcome.
HCPLive also reported EASI-75 rates above 94% by week 52 during open-label maintenance. That finding applied to both the continuous-treatment group and the group that crossed over from placebo.
The maintenance result belongs alongside the earlier findings, but its study setting needs to remain visible when interpreting it.
For the 24 µg/kg study group, HCPLive reported that the proportion achieving SALT 20 or lower increased from 15.6% at week 36 to 27.6% at week 52. This is a description of the studied group, not dosing guidance.
The report said the later increase included participants who had not received the 16-week blinded extension. That detail makes the timing of response worth further investigation. It does not show that hair continued to regrow after treatment for every participant.
These percentages describe outcomes within particular study settings. The reports do not establish what response rates would look like in everyday care.
HCPLive’s REZOLVE-AA summary does not provide full methods, participant counts, confidence intervals or detailed safety results. Without those details, the response percentages alone cannot establish the likelihood of benefit for an individual or support a complete benefit-risk assessment.
There is an important distinction between information unavailable in a report and a demonstrated weakness in the original study. The missing details should not be treated as evidence that the trial lacked them. They identify what cannot be assessed from this summary.
For telikibart, the week-52 maintenance findings were open-label. They should therefore be distinguished from the placebo-controlled week-16 comparison. The higher maintenance response rates should not be presented as though they came from an equivalent comparison with placebo.
The endpoints also address different conditions. EASI-75 and IGA 0/1 in atopic dermatitis should not be ranked against SALT 20 in alopecia areata. Comparing their percentages would confuse different clinical measures rather than clarify which treatment performed better.
Finally, neither investigational finding establishes approval or superiority over existing options. The available reporting does not support a conclusion that either candidate offers better efficacy or safety than approved treatments.
For someone managing eczema or alopecia areata, the practical value of this update is a more informed conversation. It is not a reason to start, stop or change treatment without a clinician’s advice.
The research supports several useful questions for a dermatologist:
Those questions keep the discussion focused on clinical relevance rather than on the largest number in a headline. They also separate interest in an emerging therapy from a personal treatment decision.
Readers following the wider research landscape can also consult Younell’s separate analysis of severe alopecia areata trial findings. Keeping individual study reports distinct helps preserve the differences between their endpoints and follow-up periods.
In a separate October 2026 report, Zacks said Nektar planned to initiate a registrational phase 3 rezpegaldesleukin trial in alopecia areata in early 2027. That is a reported development plan, not a confirmed clinical outcome. Zacks also characterized the candidate as investigational and tied its commercial prospects to clinical outcomes and regulatory approvals.
The evidence-bounded takeaway is specific: HCPLive reported positive placebo-controlled telikibart results at week 16 and a later rise in a rezpegaldesleukin response measure. The next useful question is how fuller study reporting and subsequent trials clarify the clinical meaning of those findings. For readers concerned about skin and hair health, that is a sounder basis for attention than assuming an emerging result already answers a treatment question.
Stay connected for research and practical guidance on skin, hair, collagen, nutrition and beauty longevity. Clear ideas for people who want to understand how appearance changes with age and make better-informed choices over time.
Understand your skin, hair and body better without chasing every new trend, treatment or promise.
explore the Blog
